Abstract
Beta-2 glycoprotein I (β2GPI) is the main antigenic target for antiphospholipid antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) of β2GPI has lately been identified as the main epitope targeted by antibodies reacting against β2GPI. DI is a cryptic epitope, becoming available for autoantibody binding when β2GPI opens from a circular to a fish-hook configuration. Antibodies targeting β2GPI-DI are more frequently detected in patients with a full-blown syndrome than in asymptomatic aPL carriers or in patients with infectious diseases that have reactivity toward the whole molecule. Interestingly, anti-DI antibodies are strongly positively correlated with thrombotic and pregnancy manifestations, enabling identification of patients at higher risk of clinical events. However, available tests to detect anti-DI antibodies still lack standardization. Moreover, some APS patients develop antibodies reacting against β2GPI epitopes other than DI, suggesting that other anti-β2GPI antibody subsets may be clinically relevant. Available evidence on anti-DI antibodies in APS is herein critically reviewed.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance • Of importance
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheum. 2011;7:330–9.
de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep. 2011;13:70–6.
Pelkmans L, de Laat B. Antibodies against domain I of be-glycoprotein I: the one and only? Lupus. 2012;21:769–72.
•• Agar C, de Groot PG, Mörgelin M, et al. Beta2-Glycoprotein I: a novel component of innate immunity. Blood. 2011;117:6939–47. This paper describes the interaction between β 2 GPI and LPS.
Laplante P, Amireault P, Subang R, et al. Interaction of β2-glycoprotein I with lipopolysaccharide leads to Toll-like receptor 4 (TLR4)-dependent activation of macrophages. J Biol Chem. 2011;286:42494–503.
Ioannou Y, Rahman A. Domain I of β2-glycoprotein I: its role as an epitope and the potential to be developed as a specific target for the treatment of the antiphospholipid syndrome. Lupus. 2010;19:400–5.
Agar C, van Os GM, Morgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116:1336–43.
Bouma B, de Groot PG, van den Elsen JM, et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipid based on its crystal structure. EMBO J. 1999;18:5166–74.
Schwarzenbacher R, Zeth K, Diederichs K, et al. Crystal structure of human beta2-glyoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 1999;18:6228–39.
Hammel M, Kriechbaum M, Gries A, et al. Solution structure of human and bovine beta(2)-glycoprotein I revealed by small-angle x-ray scattering. J Mol Biol. 2002;321:85–97.
George J, Gilburd B, Hojnik M, et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol. 1998;160:3917–23.
Koike T, Ichikawa K, Kasahara H, Atsumi T, Tsutsumi A, Matsuura E. Epitopes on β2-glycoprotein I recognized by anticardiolipin antibodies. Lupus. 1998;7:14–7.
Yang CD, Chen SL, Shen N, Qi M, Xu F. Detection of anti-recombinant β2 glycoprotein I fifth domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int. 1998;18:5–10.
Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-b2-glycoprotein I autoantibodies. Thromb Haemost. 1998;80:393–8.
Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E: Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 1999, 5164–5168.
Iverson GM, Victoria EJ, Marquis DM. Anti-β2 glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci U S A. 1998;95:15542–6.
McNeely PA, Dlott JS, Furie RA, et al. β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost. 2001;86:590–5.
Reddel SW, Wang YX, Sheng YH, Krillis SA. Epitope studies with anti-β2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmunity. 2000;15:91–6.
Iverson GM, Reddel S, Victoris EJ, et al. Use of single point mutations in domain I of β2-glycoprotein I to determine fine antibody specificity of antiphospholipid autoantibodies. J Immunol. 2002;169:7097–103.
Ioannou Y, Pericleous C, Giles I, Latchman DS, Isenberg DA, Rahman A. Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum. 2007;56:280–90.
de Laat B, Derksen RH, van Lummel M, et al. Pathogenic anti-beta2 glycoprotein I antibodies recognize domain I of beta-2 glycoprotein I only after a conformational change. Blood. 2006;107:1916–24.
•• De Laat B, van Berkel M, Urbanus RT, et al. Immune responses against domain I of β2-glycoprotein I are driven by conformational changes. Arthritis Rheum. 2011;63:3960–8. In vivo immunization against DI depends upon β 2 GPI conformation.
Giannakopoulos B, Krillis SA. The pathogenesis of the anti-phospholipid syndrome. N Eng J Med. 2013;368:1033–44.
Ioannou Y, Zhang JY, Qi M, et al. Novel assays of thrombogenic pathogenicity for the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum. 2011;63:2774–82.
Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106:2340–6.
Mahler M, Norman GL, Meroni PL, Khamashta M. Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome. Autoimmun Rev. 2012;12:313–7.
de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540–5.
Ioannou Y, Romay-Penabad Z, Pericleous C, et al. In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept. J Thromb Haemost. 2009;7:833–42.
Pericleous C, Ruiz-Limon P, Romay-Penabad Z, et al. Affinity purified antibodies directed to domain I of β2GPI are pathogenic in a mouse model of thrombosis. Arthritis Rheum. 2012;64:S740.
•• Agostinis C, Durigutto P, Sblattero D, et al. A human recombinant antibody to beta2-glycoprotein I prevents thrombus formation and fetal loss in animal models of anti-phospholipid syndrome. Arthritis Rheum. 2013;65:S245. This work provides direct evidence of the pathogenicity of anti-DI antibodies.
Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, et al. Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs. PLoS ONE. 2013;8:e71402. doi:10.1371/journal.pone.0071402.
Mahler M, Radice A, Yang W, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413:719–26.
Borghi MO, Grossi C, Pregnolato F, et al. Anti-beta2 glycoprotein I-domain I autoantibodies: comparison between two methods of detection [abstract]. Granada: VIII Congress on Autoimmunity; 2012.
Willis R, Mahler M, Pregnolato F, et al. Clinical evaluation of two anti-Beta2glycoprotein I Domain 1 autoantibody assays to aid in the diagnosis and risk assessment of the antiphospholipid syndrome. Arthritis Rheum. 2013;65:S3.
Zohoury N, Khamashta M, Atsumi T, et al. Autoantibodies targeting Domain 1 of beta 2 glycoprotein I as promising marker in the diagnosis and risk stratification of the antiphospholipid syndrome. Arthritis Rheum. 2013;65:S4.
Pozzi N, Banzato A, Bettin S, Bison E, Pengo V, De Filippis V. Chemical synthesis and characterization of wild-type and biotinylated N-terminal domain 1–64 of beta2-glycoprotein I. Protein Sci. 2010;19:1065–78.
• Banzato A, Pozzi N, Frasson R, et al. Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res. 2011;128:583–6. In this work, anti-DI antibodies were associated with high-risk triple positivity.
Albesa R, Zohoury N, Pierangeli SS, Iverson GM, Norman GM: Performance of a novel chemiluminescent test for detection of antibodies to β2GPI-domain I in patients with anti-phospholipid syndrome (APS) [abstract]. Granada: VIII Congress on Autoimmunity; 2012.
Hollestelle M, van Schangen M, Kariman A, Pequeriaux N. Antibodies against domain I of beta2-glycoprotein I are a better predictor for the antiphospholipid syndrome than antibodies to the total protein [abstract]. Amsterdam: XXIV Congress of the international society of thrombosis and haemostasis; 2013.
Albesa R, Khamashta M, Shums Z, Zohoury N, Norman G, Mahler M. Antibodies (IgG) to domain I of beta 2 glycoprotein I (β2GPI-domain I) measured by a novel chemiluminiscence assay [abstract]. Granada: 8th International Congress on Autoimmunity; 2012.
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 1827;2003:101.
de Laat B, Pengo V, Pabinger I, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost. 2009;7:1767–73.
Zuily S, De Laat B, Regnault V, et al. Autoantibodies against domain I of beta2-glycoprotein indicate an increased risk for thrombosis in antiphospholipid patients. A prospective cohort study. Arthritis Rheum. 2013;65:S1130.
Agmon-Levin N, Seguro L, Rosario C, et al. Anti-β2GPI-DI antibodies are a marker of APS severity. Arthritis Rheum. 2013;65:S1.
Andreoli L, Nalli C, Borghi MO, et al. Domain I is the main specificity of anti-beta2 GPI in systemic autoimmune diseases. Arthritis Rheum. 2013;65:S4.
Andreoli L, Nalli C, Motta M, et al. Anti-β2-glycoprotein I IgG antibodies from 1-year old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason of their innocent profile? Ann Rheum Dis. 2011;70:380–3.
de Laat B, Wu X-X, van Lummel M, Derksen RHWM, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulation activity of annexin A5. Blood. 2007;109:1490–4.
Wahezi DM, Ilowite NT, Pelkmans L, de Laat B, Schanberg LE, Rand JH. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2 glycoprotein I. Lupus. 2013;22:702–11.
Levine AB, Rand JH, Wu XX, et al. Effects of hydroxychloroquine (HCQ) on the Annexin A5 resistance assay (AnnA5-RA) in antiphospholipid antibody (aPL) positive patients: preliminary results of an ongoing prospective study. Arthritis Rheum. 2012;64:S743.
Rand JH, Wu XX, Lapinski R, et al. Detection of antibody-mediated reduction of annexin A5 anti-coagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood. 2004;104:2783–90.
Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol. 2003;163:1193–200.
Pengo V, Banzato A, Denas G, et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev. 2013;12:832–4.
Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013;11:1527–32.
Compliance with Ethics Guidelines
Conflict of Interest
Pier Luigi Meroni received an honorarium for attendance at an INOVA advisory board meeting. Cecilia Beatrice Chighizola and Maria Gerosa declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Antiphospholipid Syndrome
Rights and permissions
About this article
Cite this article
Chighizola, C.B., Gerosa, M. & Meroni, P.L. New Tests to Detect Antiphospholipid Antibodies: Anti-Domain I Beta-2-Glycoprotein-I Antibodies. Curr Rheumatol Rep 16, 402 (2014). https://doi.org/10.1007/s11926-013-0402-7
Published:
DOI: https://doi.org/10.1007/s11926-013-0402-7